Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma.

Authors :: Leypoldt LB
Tichy D
Besemer B
Hanel M
Raab MS
Mann C
Munder M
Reinhardt HC
Nogai A
Gorner M
Ko YD
de Wit M
Salwender H
Scheid C
Graeven U
Peceny R
Staib P
Dieing A
Einsele H
Jauch A
Hundemer M
Zago M
Pozek E
Benner A
Bokemeyer C
Goldschmidt H
Weisel KC
Source :: Future oncology (London, England) [Future Oncol] 2024 Dec; Vol. 20 (39), pp. 3193-3207. Date of Electronic Publication: 2024 Sep 30.
Publication Year :: 2024

Full Text Access

Tools